Clinical trial
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and…
NCT00300885 · Bayer, Industry · Terminated
Key facts
| NCT number | NCT00300885 |
|---|---|
| Title | A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC) |
| Official title | A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | Bayer, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small Cell Lung |
| Intervention type | Drug |
| Interventions | Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel, Carboplatin plus Paclitaxel |
| Enrollment | 926 |
| Start date | Feb 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Feb 1, 2009 |
| First posted | Mar 10, 2006 |
| Last update posted | Nov 4, 2014 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, Chile, France, Germany, Hong Kong, Hungary, Italy, Netherlands and 9 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: